Coronavirus Notebook: 35 Generic Firms To Produce Pfizer’s Paxlovid, AZ’s Evusheld Gains UK & Australian Approval
Executive Summary
Finland’s Rokote expects to begin clinical trials with its intranasal vaccine after the summer, while Australia’s ENA Respiratory has dosed the first patients in a Phase IIa study of its antiviral nasal spray.
You may also be interested in...
Coronavirus Notebook: Bivalent Spikevax OKd For Filing In Australia, Pfizer & Moderna Under Growing Pressure To Share mRNA Knowhow
The World Health Organization and UNICEF say that disruptions caused by COVID-19 and actions taken to tackle the pandemic have left many children without protection against measles and other diseases. Austria’s Apeiron has given an update on the development of its candidate therapeutic, APN01.
Global Biopharma CEOs Frustrated By IP Waiver Talk Amid COVID-19 Vaccine Glut
Top pharma executives claim ongoing vaccine inequity is not due to a lack of supply but to a shortage of sufficient infrastructure in low-and-middle income countries to administer available doses.
MPP Announces Generic Paxlovid Licences For LMICs
A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.